FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200548051> ?p ?o ?g. }

• W4200548051 endingPage "184" @default.
• W4200548051 startingPage "172" @default.
• W4200548051 abstract "Predictive biomarkers could allow more precise use of immune checkpoint inhibitors (ICIs) in treating advanced cancers. Given the central role of HLA molecules in immunity, variation at the HLA loci could differentially affect the response to ICIs. The aim of this epidemiological study was to determine the effect of HLA-A*03 as a biomarker for predicting response to immunotherapy.In this epidemiological study, we investigated the clinical outcomes (overall survival, progression free survival, and objective response rate) after treatment for advanced cancer in eight cohorts of patients: three observational cohorts of patients with various types of advanced tumours (the Memorial Sloan Kettering Integrated Mutation Profiling of Actionable Cancer Targets [MSK-IMPACT] cohort, the Dana-Farber Cancer Institute [DFCI] Profile cohort, and The Cancer Genome Atlas) and five clinical trials of patients with advanced bladder cancer (JAVELIN Solid Tumour) or renal cell carcinoma (CheckMate-009, CheckMate-010, CheckMate-025, and JAVELIN Renal 101). In total, these cohorts included 3335 patients treated with various ICI agents (anti-PD-1, anti-PD-L1, and anti-CTLA-4 inhibitors) and 10 917 patients treated with non-ICI cancer-directed therapeutic approaches. We initially modelled the association of HLA amino-acid variation with overall survival in the MSK-IMPACT discovery cohort, followed by a detailed analysis of the association between HLA-A*03 and clinical outcomes in MSK-IMPACT, with replication in the additional cohorts (two further observational cohorts and five clinical trials).HLA-A*03 was associated in an additive manner with reduced overall survival after ICI treatment in the MSK-IMPACT cohort (HR 1·48 per HLA-A*03 allele [95% CI 1·20-1·82], p=0·00022), the validation DFCI Profile cohort (HR 1·22 per HLA-A*03 allele, 1·05-1·42; p=0·0097), and in the JAVELIN Solid Tumour clinical trial for bladder cancer (HR 1·36 per HLA-A*03 allele, 1·01-1·85; p=0·047). The HLA-A*03 effect was observed across ICI agents and tumour types, but not in patients treated with alternative therapies. Patients with HLA-A*03 had shorter progression-free survival in the pooled patient population from the three CheckMate clinical trials of nivolumab for renal cell carcinoma (HR 1·31, 1·01-1·71; p=0·044), but not in those receiving control (everolimus) therapies. Objective responses were observed in none of eight HLA-A*03 homozygotes in the ICI group (compared with 59 [26·6%] of 222 HLA-A*03 non-carriers and 13 (17·1%) of 76 HLA-A*03 heterozygotes). HLA-A*03 was associated with shorter progression-free survival in patients receiving ICI in the JAVELIN Renal 101 randomised clinical trial for renal cell carcinoma (avelumab plus axitinib; HR 1·59 per HLA-A*03 allele, 1·16-2·16; p=0·0036), but not in those receiving control (sunitinib) therapy. Objective responses were recorded in one (12·5%) of eight HLA-A*03 homozygotes in the ICI group (compared with 162 [63·8%] of 254 HLA-A*03 non-carriers and 40 [55·6%] of 72 HLA-A*03 heterozygotes). HLA-A*03 was associated with impaired outcome in meta-analysis of all 3335 patients treated with ICI at genome-wide significance (p=2·01 × 10-8) with no evidence of heterogeneity in effect (I2 0%, 95% CI 0-0·76) INTERPRETATION: HLA-A*03 is a predictive biomarker of poor response to ICI. Further evaluation of HLA-A*03 is warranted in randomised trials. HLA-A*03 carriage could be considered in decisions to initiate ICI in patients with cancer.National Institutes of Health, Merck KGaA, and Pfizer." @default.
• W4200548051 created "2021-12-31" @default.
• W4200548051 creator A5001700576 @default.
• W4200548051 creator A5012908005 @default.
• W4200548051 creator A5015541994 @default.
• W4200548051 creator A5015912472 @default.
• W4200548051 creator A5037451699 @default.
• W4200548051 creator A5044886059 @default.
• W4200548051 creator A5050974773 @default.
• W4200548051 creator A5052504518 @default.
• W4200548051 creator A5058798835 @default.
• W4200548051 creator A5060945949 @default.
• W4200548051 creator A5062235853 @default.
• W4200548051 creator A5069300441 @default.
• W4200548051 creator A5070669850 @default.
• W4200548051 creator A5076758822 @default.
• W4200548051 creator A5079990486 @default.
• W4200548051 creator A5080842226 @default.
• W4200548051 creator A5091176592 @default.
• W4200548051 date "2022-01-01" @default.
• W4200548051 modified "2023-10-16" @default.
• W4200548051 title "HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study" @default.
• W4200548051 cites W1581904411 @default.
• W4200548051 cites W1974872064 @default.
• W4200548051 cites W2031758879 @default.
• W4200548051 cites W2037918327 @default.
• W4200548051 cites W2098951833 @default.
• W4200548051 cites W2104549677 @default.
• W4200548051 cites W2116243022 @default.
• W4200548051 cites W2143813821 @default.
• W4200548051 cites W2148706732 @default.
• W4200548051 cites W2170658573 @default.
• W4200548051 cites W2222086386 @default.
• W4200548051 cites W2371138393 @default.
• W4200548051 cites W2474836229 @default.
• W4200548051 cites W2604441970 @default.
• W4200548051 cites W2765417948 @default.
• W4200548051 cites W2771737095 @default.
• W4200548051 cites W2774712455 @default.
• W4200548051 cites W2782183686 @default.
• W4200548051 cites W2804812017 @default.
• W4200548051 cites W2911812451 @default.
• W4200548051 cites W2912282469 @default.
• W4200548051 cites W2920270836 @default.
• W4200548051 cites W2941582519 @default.
• W4200548051 cites W2961686530 @default.
• W4200548051 cites W3029490475 @default.
• W4200548051 cites W3037355837 @default.
• W4200548051 cites W3083058958 @default.
• W4200548051 cites W3104635171 @default.
• W4200548051 cites W3107249307 @default.
• W4200548051 cites W3112460114 @default.
• W4200548051 cites W4247154971 @default.
• W4200548051 doi "https://doi.org/10.1016/s1470-2045(21)00582-9" @default.
• W4200548051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34895481" @default.
• W4200548051 hasPublicationYear "2022" @default.
• W4200548051 type Work @default.
• W4200548051 citedByCount "40" @default.
• W4200548051 countsByYear W42005480512022 @default.
• W4200548051 countsByYear W42005480512023 @default.
• W4200548051 crossrefType "journal-article" @default.
• W4200548051 hasAuthorship W4200548051A5001700576 @default.
• W4200548051 hasAuthorship W4200548051A5012908005 @default.
• W4200548051 hasAuthorship W4200548051A5015541994 @default.
• W4200548051 hasAuthorship W4200548051A5015912472 @default.
• W4200548051 hasAuthorship W4200548051A5037451699 @default.
• W4200548051 hasAuthorship W4200548051A5044886059 @default.
• W4200548051 hasAuthorship W4200548051A5050974773 @default.
• W4200548051 hasAuthorship W4200548051A5052504518 @default.
• W4200548051 hasAuthorship W4200548051A5058798835 @default.
• W4200548051 hasAuthorship W4200548051A5060945949 @default.
• W4200548051 hasAuthorship W4200548051A5062235853 @default.
• W4200548051 hasAuthorship W4200548051A5069300441 @default.
• W4200548051 hasAuthorship W4200548051A5070669850 @default.
• W4200548051 hasAuthorship W4200548051A5076758822 @default.
• W4200548051 hasAuthorship W4200548051A5079990486 @default.
• W4200548051 hasAuthorship W4200548051A5080842226 @default.
• W4200548051 hasAuthorship W4200548051A5091176592 @default.
• W4200548051 hasBestOaLocation W42005480512 @default.
• W4200548051 hasConcept C107130276 @default.
• W4200548051 hasConcept C121608353 @default.
• W4200548051 hasConcept C126322002 @default.
• W4200548051 hasConcept C143998085 @default.
• W4200548051 hasConcept C185592680 @default.
• W4200548051 hasConcept C203014093 @default.
• W4200548051 hasConcept C2780352672 @default.
• W4200548051 hasConcept C2781068499 @default.
• W4200548051 hasConcept C2781197716 @default.
• W4200548051 hasConcept C535046627 @default.
• W4200548051 hasConcept C55493867 @default.
• W4200548051 hasConcept C71924100 @default.
• W4200548051 hasConcept C72563966 @default.
• W4200548051 hasConceptScore W4200548051C107130276 @default.
• W4200548051 hasConceptScore W4200548051C121608353 @default.
• W4200548051 hasConceptScore W4200548051C126322002 @default.
• W4200548051 hasConceptScore W4200548051C143998085 @default.
• W4200548051 hasConceptScore W4200548051C185592680 @default.
• W4200548051 hasConceptScore W4200548051C203014093 @default.

• next